Amazon Stock Dips Despite Record Earnings as AI Infrastructure Spending Surges 
Air Liquide Q1 Revenue Misses Estimates Amid Currency and Energy Headwinds 
Microsoft Azure Growth Forecast Beats Expectations Amid Rising AI Competition 
Ford Q1 Earnings Beat Expectations, Stock Surges on Strong Guidance 
Novartis Q1 2026 Earnings Miss Expectations as Generic Competition Pressures Sales 
Samsung Reports Record Profit as AI Boom Drives Memory Chip Demand 
Pershing Square Raises $5 Billion in Landmark U.S. IPO and Share Placement 
Alphabet Earnings Surge on AI Growth, Cloud Revenue, and Strong Search Performance 
Standard Chartered Q1 Profit Hits Record on Wealth and Investment Banking Growth 
OpenAI Faces Revenue Pressure and User Growth Challenges Ahead of IPO 
Lightelligence IPO Soars Over 400% in Hong Kong Debut Amid Rising AI Investment Demand 
TSMC Exits Arm Holdings with $231 Million Share Sale Amid Strategic Portfolio Shift 
Micro Systemation Reports Q1 Loss Amid Strategic Investments and Revenue Growth 
Google Secures Pentagon AI Deal for Classified Projects 
Seagate Stock Surges After Strong Q3 Earnings Beat and Bullish Outlook 
Advantest Stock Falls on Weak Outlook Despite Strong AI-Driven Results 
T-Mobile Beats Q1 Earnings Expectations on Strong Postpaid Growth 
BASEL, Switzerland and CAMBRIDGE, Mass., April 27, 2017 -- CRISPR Therapeutics (NASDAQ:CRSP), a biopharmaceutical company focused on translating CRISPR-Cas9 gene-editing technology into transformative medicines, today announced that Rodger Novak, M.D., Chief Executive Officer and Founder of CRISPR Therapeutics, will present at the 42nd Annual Deutsche Bank Health Care Conference on Wednesday, May 3, 2017 at the InterContinental Boston Hotel in Boston, MA.
Event: 42nd Annual Deutsche Bank Health Care Conference
Date: Wednesday, May 3rd
Time: 4:10 PM EDT
A live webcast of the presentation can be accessed under "Events & Presentations" in the Investors & Media section of the Company's website at www.crisprtx.com.
About CRISPR Therapeutics
CRISPR Therapeutics is a leading gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 gene-editing platform. CRISPR / Cas9 is a revolutionary technology that allows for precise, directed changes to genomic DNA. The company's multi-disciplinary team of world-class researchers and drug developers is working to translate this technology into breakthrough human therapeutics in a number of serious diseases. Additionally, CRISPR Therapeutics has established strategic collaborations with Bayer AG and Vertex Pharmaceuticals to develop CRISPR-based therapeutics in diseases with high unmet need. The foundational CRISPR/Cas9 patent estate for human therapeutic use was licensed from the company's scientific founder Emmanuelle Charpentier, Ph.D. CRISPR Therapeutics is headquartered in Basel, Switzerland with its R&D operations based in Cambridge, Massachusetts. For more information, please visit www.crisprtx.com.
MEDIA CONTACTS: Jennifer Paganelli WCG on behalf of CRISPR +1 347-658-8290 [email protected] INVESTOR CONTACT: Chris Brinzey Westwicke Partners for CRISPR +1 339-970-2843 [email protected]
